Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Executive Summary: The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.

Rheumatology (Oxford, England)·2026
Same author

The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.

Rheumatology (Oxford, England)·2026
Same author

Identifying strategies to improve life participation in children with chronic kidney disease: report from multinational SONG workshops.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Triple Therapy With Calcineurin Inhibition Enhances Remission in Childhood-Onset Lupus Nephritis.

Kidney international reports·2026
Same author

Kidney Transplantation in Childhood-Onset ANCA-Associated Vasculitis: Long-Term Outcomes and Prognostic Factors.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

The psychosocial factors influencing paediatric kidney transplantation access, their outcomes and the patient and family's perceived quality of life: a systematic review and meta-analysis.

Pediatric nephrology (Berlin, Germany)·2025
Same journal

Single-Center Experience in Pediatric Lung Transplantation: Clinical Characteristics, Survival, and Post-Transplant Morbidity.

Pediatric transplantation·2026
Same journal

The Missing Link Between HLA Mismatch and Graft Failure: The Role of Donor-Specific Antibodies.

Pediatric transplantation·2026
Same journal

Truth or Consequences Revisited: Policymaking in Modern Organ Transplant.

Pediatric transplantation·2026
Same journal

First Single-Center Experience of Minimally Invasive Pediatric Living Donor Liver Transplantation in China.

Pediatric transplantation·2026
Same journal

Liver Retransplantation in Pediatric Recipients: A 20-Year Single-Center Experience With 25 Cases.

Pediatric transplantation·2026
Same journal

The Use of Ambulatory Blood Pressure Monitoring in Pediatric Heart Transplant Recipients.

Pediatric transplantation·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Induction therapy: why, when, and which agent?

Leah Krischock1, Stephen D Marks

  • 1Department of Paediatric Nephrology, Royal Hospital for Sick Children, Glasgow, UK.

Pediatric Transplantation
|March 30, 2010
PubMed
Summary
This summary is machine-generated.

Induction therapy using antibody agents improves outcomes in pediatric solid organ transplantation by reducing early injury and enabling lower maintenance immunosuppression doses. This strategy aims to enhance long-term allograft survival and minimize rejection.

More Related Videos

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods
09:23

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Published on: October 10, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Related Experiment Videos

Last Updated: Jun 14, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods
09:23

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Published on: October 10, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Pediatric Medicine

Background:

  • Paediatric transplantation outcomes have improved due to advancements in immunosuppressive agents.
  • Despite progress, managing the immune response remains a critical challenge in transplantation.
  • Early graft injury and long-term allograft survival are key concerns.

Purpose of the Study:

  • To review the current literature on antibody induction therapy in paediatric solid organ transplantation.
  • To evaluate the role of induction immunosuppression in optimizing long-term graft survival.
  • To assess the impact of induction therapy on maintenance immunosuppression requirements.

Main Methods:

  • Systematic review of existing literature.
  • Analysis of studies focusing on antibody induction agents in paediatric solid organ transplants.
  • Evaluation of outcomes related to acute rejection, chronic damage, and graft survival.

Main Results:

  • Induction therapy can mitigate early post-transplant injury.
  • It allows for reduced doses of maintenance immunosuppressive agents.
  • The goal is to prevent acute rejection and chronic allograft damage.

Conclusions:

  • Antibody induction therapy is a valuable strategy in paediatric solid organ transplantation.
  • It plays a crucial role in improving long-term allograft survival.
  • Optimizing induction protocols is essential for minimizing immunosuppression-related toxicities.